NCT00843531 2020-09-29RAD001 and Erlotinib in Patients With Neuroendocrine TumorsUniversity of California, San FranciscoPhase 2 Terminated17 enrolled 10 charts
NCT00947167 2017-03-03A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsStanford UniversityPhase 2 Terminated4 enrolled 5 charts